• Japanese
  • Korean
  • Chinese
Cover Image

Global Liver Cancer Partnering 2010-2015

Provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies .

Description

The Liver Cancer Partnering 2010-2015 report provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in liver cancer partnering deals

Top Liver cancer deals by value

Deals listed by company A-Z, industry sector, stage of development, technology type

The Liver Cancer Partnering 2010-2015 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains over 35 links to online copies of actual liver cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of liver cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Liver cancer technologies and products.

Report scope

Liver Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to Liver cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in Liver cancer dealmaking in the biopharma industry since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 35 livercancer deals and contract documents where available
  • The leading Liver cancer deals by value since 2010

In Liver Cancer Partnering 2010-2015, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Liver Cancer Partnering 2010-2015 provides the reader with the following key benefits:

  • In-depth understanding of liver cancer deal trends since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 50 actual liver cancer deals entered into by the world's biopharma companies since 2010
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Liver cancer partnering

  • 2.1. Introduction
  • 2.2. Liver cancer partnering over the years
  • 2.3. Liver cancer partnering by deal type
  • 2.4. Liver cancer partnering industry sector
  • 2.5. Liver cancer partnering by stage of development
  • 2.6. Liver cancer partnering by technology type

Chapter 3 - Average deal terms for Liver cancer

  • 3.1 Introduction
  • 3.2 Average deal terms for Liver cancer
  • 3.3 Liver cancer headline values with median calculation
  • 3.4 Liver cancer upfront values with median calculation
  • 3.5 Liver cancer milestone values with median calculation
  • 3.6 Liver cancer royalty rates with median calculation

Chapter 4 - Active Liver cancer dealmakers

  • 4.1. Introduction
  • 4.2 Most active Liver cancer dealmakers
  • 4.3. Top Liver cancer deals by value
  • 4.4 Big pharma deal activity
  • 4.5 Big biotech deal activity

Chapter 5 - Liver cancer dealmaking directory

  • 5.1. Introduction
  • 5.2. Company A-Z
  • 5.3. By deal type
  • 5.4. By industry sector
  • 5.5. By stage of development
  • 5.6. By technology type

Chapter 6 - Partnering resource center

  • 6.1. Online partnering
  • 6.2. Partnering events
  • 6.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering
  • Order Form - Reports
  • Order Form - Subscription Access Products
  • Table of figures
  • Figure 1: Liver cancer partnering since 2010
  • Figure 2: Liver cancer dealmaking activity- 2010 to 2015
  • Figure 3: Liver cancer partnering by deal type since 2010
  • Figure 4: Liver cancer partnering by industry sector since 2010
  • Figure 5: Liver cancer partnering by stage of development since 2010
  • Figure 6: Liver cancer partnering by technology type since 2010
  • Figure 7: Liver cancer deals with a headline value
  • Figure 8: Liver cancer deals with upfront payment values
  • Figure 9: Liver cancer deals with milestone payments
  • Figure 10: Liver cancer deals with royalty rates, %
  • Figure 11: Top Liver cancer deals by value since 2010
  • Figure 12: Big pharma - top 50 - Liver cancer deals 2010 to 2015
  • Figure 13: Big pharma Liver cancer deal frequency - 2010 to 2015
  • Figure 14: Big biotech - top 50 - Liver cancer deals 2010 to 2015
  • Figure 15: Big biotech Liver cancer deal frequency - 2010 to 2015
  • Figure 16: Online partnering resources
  • Figure 17: Forthcoming partnering events
  • Figure 18: Deal type definitions
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top